SIGA Technologies (NASDAQ:SIGA) announced Thursday that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved ...

The approval of TEPOXX in Japan marks another significant milestone in our mission to expand access to this critical ...

On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment ...

Infection with mpox causes a fever and swollen lymph nodes, followed by a distinctive rash that develops into pus-filled blisters. Currently, two companies of Japan and Denmark produce the vaccine ...

Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan ...

Siga Technologies (SIGA)’ antiviral treatment Tepoxx, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as ...

Our reporter went to Congo, where the mpox epidemic has reached the teeming capital, infecting children and their mothers, ...

DAKAR, Dec 12 (Reuters) - Democratic Republic of Congo should start to receive three million doses of mpox vaccine from Japan next week that can be used on children, the Africa Centres for Disease ...

Mpox vaccines that young children can use will arrive from Japan next week, a crucial step in reducing the spread of the disease that has killed about 1,200 people in the Democratic Republic of ...

The antiviral drug tecovirimat does not reduce the time to lesion resolution or pain among adults with mild-to-moderate clade ...

The Democratic Republic of Congo should start to receive 3 million doses of mpox vaccine from Japan next week that can be used for children, the Africa Centers for Disease Control and Prevention ...